Long-term Proton Pump Inhibitor Administration Worsens Atrophic Corpus Gastritis and Promotes Adenocarcinoma Development in Mongolian Gerbils Infected with Helicobacter Pylori
Overview
Affiliations
Background: We investigated whether corpus atrophic gastritis worsens in Mongolian gerbils (MGs) after long-term administration of proton pump inhibitor (PPI). MGs are an excellent model for studying Helicobacter pylori-related gastritis and adenocarcinoma.
Methods: MGs were separated into four groups (n =15/group); H pylori (ATCC43504) was inoculated into the OPZ(omeprazole)+Hp (H pylori) and Hp groups, a PPI (OPZ) was administered to the OPZ+Hp and OPZ groups and the control group received no treatment. MGs had access to food containing omeprazole (100 mg/kg body weight/day) for 6 months, after which their stomachs were removed and cut into nine sections (six sections in the fundus and three sections in the antrum). Corpus atrophy was evaluated by the absence of parietal cells in the six sections in the fundus. First, we calculated a percentage of the area devoid of parietal cells in each haematoxylin and eosin-stained section, and then we scored the degree of atrophy by adding the percentages of the six sections. A full score was 600.
Results: Neutrophilic and lymphoid infiltrates were greater in the OPZ+Hp group than in the other groups. The corpus atrophy score in the OPZ+Hp group was significantly higher than that in the Hp group (p < 0.0048, Student t test). Significantly more adenocarcinomas were found in the OPZ+Hp (60%) than in the Hp (7%) group animals.
Conclusion: Long-term PPI administration promotes development of adenocarcinoma, which is associated with the progression of atrophic corpus gastritis in MGs infected with H pylori.
Song D, Chen M, Chen X, Xu J, Wu S, Lyu Y BMC Complement Med Ther. 2024; 24(1):309.
PMID: 39160561 PMC: 11334567. DOI: 10.1186/s12906-024-04605-z.
CRISPLD1 promotes gastric cancer progression by regulating the Ca/PI3K-AKT signaling pathway.
Hu L, Shi J, Zhu Z, Lu X, Jiang H, Yu H Heliyon. 2024; 10(5):e27569.
PMID: 38486747 PMC: 10938123. DOI: 10.1016/j.heliyon.2024.e27569.
Ikeda S, Takahashi T, Tandoh T, Ushiyama K, Kida Y Intern Med. 2024; 63(5):649-657.
PMID: 38432892 PMC: 10982011. DOI: 10.2169/internalmedicine.2091-23.
Deep learning driven de novo drug design based on gastric proton pump structures.
Abe K, Ozako M, Inukai M, Matsuyuki Y, Kitayama S, Kanai C Commun Biol. 2023; 6(1):956.
PMID: 37726448 PMC: 10509173. DOI: 10.1038/s42003-023-05334-8.
Zheng Z, Lu Z, Song Y Front Pharmacol. 2023; 14:1244400.
PMID: 37693896 PMC: 10492503. DOI: 10.3389/fphar.2023.1244400.